CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Authors
Adrian Egli
Ajit Varki
+23 more
Alexandar Tzankov
Alfred Zippelius
Christopher I. Amos
Daniel E. Speiser
Daniela S. Thommen
Didier Lardinois
Frank Stenner
Heinz Läubli
Heinz-Josef Lenz
Kayluz Frias Boligan
Legat
Lothar Tietze
Marcel P. Trefny
Michael von Bergwelt-Baildon
Michal A. Stanczak
Mohammedyaseen Syedbasha
Perdicchio
Schaefer
Shoib S. Siddiqui
Stephan von Gunten
Viola Heinzelmann-Schwarz
Wu Zhang
Younghun Han
Publication date
1 January 2018
Publisher
'American Society for Clinical Investigation'
Doi
Cite
Abstract
© 2018, American Society for Clinical Investigation. This article has been published in final form at https://doi.org/10.1172/JCI120612First-generation immune checkpoint inhibitors, including anti-CTLA-4 and anti-programmed death 1 (anti-PD-1) antibodies, have led to major clinical progress, yet resistance frequently leads to treatment failure. Thus, new targets acting on T cells are needed. CD33-related sialic acid-binding immunoglobulin-like lectins (Siglecs) are pattern-recognition immune receptors binding to a range of sialoglycan ligands, which appear to function as self-associated molecular patterns (SAMPs) that suppress autoimmune responses. Siglecs are expressed at very low levels on normal T cells, and these receptors were not until recently considered as interesting targets on T cells for cancer immunotherapy. Here, we show an upregulation of Siglecs, including Siglec-9, on tumor-infiltrating T cells from non-small cell lung cancer (NSCLC), colorectal, and ovarian cancer patients. Siglec-9-expressing T cells coexpressed several inhibitory receptors, including PD-1. Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anticancer immunity. T cell expression of Siglec-9 in NSCLC patients correlated with reduced survival, and Siglec-9 polymorphisms showed association with the risk of developing lung and colorectal cancer. Our data identify the sialoglycan-SAMP/Siglec pathway as a potential target for improving T cell activation for immunotherapy.Peer reviewe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 27/12/2020
University of Hertfordshire Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:uhra.herts.ac.uk:2299/2401...
Last time updated on 09/03/2021
Serveur académique lausannois
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:serval.unil.ch:BIB_BD37650...
Last time updated on 13/03/2019
Bern Open Repository and Information System (BORIS)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:boris.unibe.ch:119798
Last time updated on 09/07/2019
Kölner UniversitätsPublikationsServer
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:USBKOELN.ub.uni-koeln.de:1...
Last time updated on 22/10/2020